Terms: = Lymphoma AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
79 results:
1. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
2. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
Nakano K
Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
[TBL] [Abstract] [Full Text] [Related]
3. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
4. Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.
Chi SA; Yu H; Choi YL; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Choi DH; Kim K; Jung HA; Park K
JAMA Netw Open; 2023 Mar; 6(3):e232002. PubMed ID: 36929402
[TBL] [Abstract] [Full Text] [Related]
5. Advances in the Diagnosis and treatment of a Driving Target: ret Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y
Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459
[TBL] [Abstract] [Full Text] [Related]
6. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
[TBL] [Abstract] [Full Text] [Related]
7. Alectinib for the treatment of pretreated ret-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
Felip E; Smit EF; Molina-Vila MA; Dafni U; Massuti B; Berghmans T; de Marinis F; Passiglia F; Dingemans AC; Cobo M; Viteri S; Britschgi C; Cuffe S; Provencio M; Merkelbach-Bruse S; Andriakopoulou C; Kammler R; Ruepp B; Roschitzki-Voser H; Peters S; Wolf J; Stahel R;
Lung Cancer; 2022 Oct; 172():94-99. PubMed ID: 36030612
[TBL] [Abstract] [Full Text] [Related]
8. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract] [Full Text] [Related]
9. RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center.
Luca C; Pepe F; Pisapia P; Iaccarino A; Righi L; Listì A; Russo G; Campione S; Pagni F; Nacchio M; Conticelli F; Russo M; Fabozzi T; Vigliar E; Bellevicine C; Rocco D; Laudati S; Iannaci G; Daniele B; Gridelli C; Cortinovis DL; Novello S; Molina-Vila MA; Rosell R; Troncone G; Malapelle U
Per Med; 2022 Sep; 19(5):395-401. PubMed ID: 35801400
[No Abstract] [Full Text] [Related]
10. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract] [Full Text] [Related]
11. Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review.
Nishiyama A; Hattori Y; Takeuchi S; Tanimoto A; Satouchi M; Murayama T; Yano S
Intern Med; 2022 Jun; 61(11):1735-1738. PubMed ID: 34803090
[TBL] [Abstract] [Full Text] [Related]
12. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.
Krawczyk P; Grenda A; Terlecka P; Błach J; Wojas-Krawczyk K; Kucharczyk T; Chmielewska I; Kieszko R; Jarosz B; Gil M; Reszka K; Milanowski J
Sci Rep; 2021 Oct; 11(1):20939. PubMed ID: 34686712
[TBL] [Abstract] [Full Text] [Related]
13. [Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].
de la Fouchardière C; Wassermann J; Calcagno F; Bardet S; Al Ghuzlan A; Borget I; Borson Chazot F; Do Cao C; Buffet C; Zerdoud S; Decaussin-Petrucci M; Godbert Y; Leboulleux S
Bull Cancer; 2021 Nov; 108(11):1044-1056. PubMed ID: 34593218
[TBL] [Abstract] [Full Text] [Related]
14. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
[TBL] [Abstract] [Full Text] [Related]
15. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract] [Full Text] [Related]
16. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
[TBL] [Abstract] [Full Text] [Related]
17. An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer.
Schokrpur S; Hilburn V; Giustini N; Bazhenova L
Expert Opin Pharmacother; 2021 Oct; 22(14):1815-1824. PubMed ID: 34225542
[No Abstract] [Full Text] [Related]
18. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS; Nagasaka M; Zhu VW; Ou SI
Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
[TBL] [Abstract] [Full Text] [Related]
19. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
[TBL] [Abstract] [Full Text] [Related]
20. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
[TBL] [Abstract] [Full Text] [Related]
[Next]